Merck has agreed to acquire clinical-stage biotech company Prometheus Biosciences for $200 per share in cash, with the deal expected to close late in Q2 or early in Q3. The acquisition will advance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback